thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
trans-splicing A form of RNA splicing in which different RNA transcripts, synthesized in separate transcription events, are spliced together into a single, continuous transcript. This contrasts with the more conventional "cis-splicing", where segments of the same transcript are excised or re-arranged.
=== Disability and death === Due to distance, Hodgkin decided not to attend the 1987 Congress of the International Union of Crystallography in Australia. However, despite increasing frailty, she astounded close friends and family by going to Beijing for the 1993 Congress, where she was welcomed by all. She died in July 1994 after a stroke, at her husband's home in the village of Ilmington, near Shipston-on-Stour, Warwickshire.
=== Event appearances === Pert was honored by the New York Open Center on November 7, 2006, for her "leadership across the bridge between science and heart." Pert received the first time award of the Theophrastus Paracelsus Foundation in Holistic Medicine for her pioneering work in the area of psychoneuroimmunology (St Gallen, Switzerland) on April 12, 2008.
Sources: en.wikipedia.org
== Selected publications == Eaton, D. L., & Groopman, J. D. (Eds.). (1994). The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance. Academic Press. ISBN 978-0122282553. Ramsdell, H. S., & Eaton, D. L. (1990). Species differences in aflatoxin B1 metabolism in hepatic microsomes and hepatocytes from monkey, rat, mouse, and chicken. Toxicol. Appl. Pharmacol., 105(2), 216–225. Gallagher, E. P., Wienkers, L. C., Stapleton, P. L., Kunze, K. L., & Eaton, D. L. (1994). Role of human microsomal cytochrome P4503A4 and 1A2 in the bioactivation of aflatoxin B1. Cancer Research, 54(1), 101–108. Eaton, D. L., & Bammler, T. K. (1999). Concise review of the glutathione S-transferases and their significance in toxicology. Toxicological Sciences, 49(2), 156–164. National Academies of Sciences, Engineering, and Medicine; Eaton, D. L. et al. (Eds.). (2018). Public Health Consequences of E-Cigarettes. The National Academies Press. ISBN 978-0309468336. Chang, S.-Y., Weber, E. J., Sidorenko, V. S., Chapron, A., Yeung, C. K., Gao, C., Mao, Q., Shen, D., Wang, J., Rosenquist, T. A., Dickman, K. G., Grollman, A. P., *Kelly, E. J., Himmelfarb, J., & Eaton, D. L. (2017). Human liver-kidney microphysiological system for quantum dot toxicity testing and aristolochic acid nephrotoxicity modeling. JCI Insight, 2(6), e91320 Omenn GS & Eaton DL. (2022). The Risk Assessment-Risk Management Paradigm. IN: M. Robson and WA Toscano, Ed. Risk Assessment for Environmental Health, 2nd Edition, Chapter 2, John Wiley & Sons, New York.
=== Emerald Twilight and beyond === In Emerald Twilight, Hal Jordan is driven to insanity and becomes the villain Parallax following the destruction of his hometown Coast City. He attacks Boodikka, cuts off her right hand, and takes her power ring, leaving her for dead. Boodikka is later revealed to have survived, but has been placed in suspended animation by the Manhunters along with many other former Green Lanterns, with the Manhunters intending to harness their energy to create more advanced Manhunters. After being freed, Boodikka is shocked that she no longer has her hand, and appears to remember nothing past her encounter with Parallax. During a later confrontation with the Manhunters, Kreon is killed and his ring chooses Boodikka. She resumes her duties in the Green Lantern Corps, replacing her lost hand with a Lantern construct.
In a recent but highly controversial interpretation, it has also been speculated that olfactory receptors might really sense various vibrational energy-levels of a molecule rather than structural motifs via quantum coherence mechanisms. As evidence it has been shown that flies can differentiate between two odorant molecules which only differ in hydrogen isotope (which will drastically change vibrational energy levels of the molecule). Not only could the flies distinguish between the deuterated and non-deuterated forms of an odorant, they could generalise the property of "deuteratedness" to other novel molecules. In addition, they generalised the learned avoidance behaviour to molecules which were not deuterated but did share a significant vibration stretch with the deuterated molecules, a fact which the differential physics of deuteration (below) has difficulty in accounting for. Deuteration changes the heats of adsorption and the boiling and freezing points of molecules (boiling points: 100.0 °C for H2O vs. 101.42 °C for D2O; melting points: 0.0 °C for H2O, 3.82 °C for D2O), pKa (i.e., dissociation constant: 9.71 × 10−15 for H2O vs. 1.95 × 10−15 for D2O, cf. heavy water) and the strength of hydrogen bonding. Such isotope effects are exceedingly common, and so it is well known that deuterium substitution will indeed change the binding constants of molecules to protein receptors. It has been claimed that human olfactory receptors are capable of distinguishing between deuterated and undeuterated isotopomers of cyclopentadecanone by vibrational energy level sensing.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.